Faron Pharmaceuticals Oy FARN
LSE · United Kingdom · Health Technology
GBp 35.25-1.25 (-3.42%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
First clinical evaluation of bexmarilimab plus nivolumab in patients with anti-PD-1-resistant solid tumorsTURKU, FI / ACCESS Newswire / October 1, 2026 / Ltd. (HEL:FARON)(LSE:FARN) , a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system, today announces that the first patient has been dosed in the Phase 1/2 BLAZE investigator-initiated trial.
TURKU, FI / ACCESS Newswire / September 30, 2026 / (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company and Heights Capital Management, Inc. ("HCM") have mutually agreed to defer the amortisation payment of the First and Second Tranche Bonds (as defined below) scheduled for 2 October 2026.
TURKU, FI / ACCESS Newswire / September 17, 2026 / (HEL:FARON)(LSE:FARN)TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: OY 1b.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.